Rx Communications Group, LLC

Rx Communications Group, LLC

Capabilities Overview

2000 – 2015: Providing award-winning communications counsel to life sciences and health care companies

ABOUT Rx COMMUNICATIONS

Specialists in the life science and health care industries

Partner-driven -- Senior level counsel on EVERY account

Navigate clients through up and down market cycles, various political health care agendas and technology trends

ABOUT Rx COMMUNICATIONS

Experience with private and public companies – domestic and international

Focused on what we do best: Investor Relations and Financial/Science Media Relations

Strong Wall Street and media contacts

Headquartered in New York City; partnered with Consilium Strategic Communications in London

PRIVATE COMPANIES

Services for Private Companies

WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY?

Lay the groundwork for future financings and eventual IPO

Assist with partnering activities by building corporate awareness

Build awareness of disease indications to generate product interest

Align company with reputable bankers

Become accustomed to working within disclosure rules i.e., Reg. FD

PROVIDING VALUE TO PRIVATE COMPANIES

Develop key messages positioned for analysts and investors

Develop collateral materials to tell story integrating key messages

Target and facilitate introductions to venture capitalists and institutional investors

Target and advise on corporate finance team

Target and facilitate introductions to sell-side analysts

PROVIDING VALUE TO PRIVATE COMPANIES

Build presence on the web

Review upcoming newsworthy events and develop story ideas for the media

Cultivate reporter interest

Introduce to conference circuit

Strategically position company news to optimize impact

Develop company disclosure policy

ACTIVITIES SURROUNDING IPO

Assist in the selection of banking team – beginning of quiet period

Press release announcing registration for offering

Develop roadshow presentation

Supplement banker’s list of target institutions

Presentation training

ACTIVITIES SURROUNDING IPO

“Teach-ins” at banks

Roadshow

Press release announcing completion of IPO

Create disclosure policy

Quiet period compliance

PUBLIC COMPANIES

Services for Public Companies

AFTER-MARKET SUPPORT

Need for continual dialogue with shareholders

Ongoing targeting of investors for future financings

Increase analyst coverage beyond banking support

Fulfill disclosure requirements

Crisis communications

Strategic media outreach

GETTING STARTED: FIRST STEPS

Strategy session in order to immerse ourselves in corporate story

Define key message points

Understand perceptions existent in the marketplace

Create targeted list of sell-side analysts, venture capitalists and fund managers

GETTING STARTED: FIRST STEPS

Review collateral materials

Create VIP blast e-mail/fax lists

Develop media lists

Design action plan

Rx COMMUNICATIONS CAPABILITIES

Strategic Counsel

Roadshows

Analyst Contact

Investor Targeting

Investment and Industry Conferences

Follow-up and Analysis to Key Events

Press Release Writing

News Conferences/Press Briefings

Video/Radio News Releases

Fact Sheets

Annual Reports

Rx COMMUNICATIONS CAPABILITIES

Crisis Communications

Mergers and Acquisitions

Positioning Strategy

Perception Audits

Conference Calls

Presentation Training

Placement Strategy

Financial, Trade and Local Media Contacts

Slide Presentations

Web Site Development

THE Rx TEAM

Melody A. Carey, President

Founded Rx Communications in 2000

Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc.

Director of Investor Relations,

The Multicare Companies, Inc.

Executive, Noonan/Russo Communications

Former health care/life sciences investment banker, Kidder, Peabody & Co.

THE Rx TEAM

Rhonda Chiger, Senior AdvisorFounded Rx Communications in 2000Senior Managing Director, Global Consulting Practice, Thomson FinancialManaged Life Sciences departments for Noonan/Russo and Dewe RogersonEstablished London office for health care investor relations firmManager, Investor Relations, American Stock Exchange

THE Rx TEAM

Paula B. Schwartz

, Managing Director

Twelve years with Rx Communications

Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S.

Vice President, ECOM Consultants, Inc., an investor relations firm

Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy

THE Rx TEAM

Steve Silver, Senior Vice President

Joined Rx Communications in April 2015

More than15 years of professional experience as a Wall Street analyst focused on healthcare and an investor relations specialist

Senior Industry Equity Analyst at S&P Capital IQ, covering Biotechnology and Healthcare Facilities

Senior Investor Relations Manager, Anne McBride Company and Global Consulting Group (both now part of Grayling)

THE Rx TEAM

Stacey Jurchison, Investor Relations Specialist

20 years specialized experience as dedicated in-house IR life sciences practitioner

Director of Investor Relations for PharmAthene, Inc. and Guilford Pharmaceuticals, Inc.

Developed and implemented IR programs that included M&A activities as well as corporate litigation.

THE Rx TEAM

Jules Abraham, Senior Media

Consultant

Nearly 20 years of healthcare public relations experience representing large and specialty pharmaceuticals, biotechnology, medical devices, clinical diagnostics, healthcare IT, healthcare services 

Supported market conditioning, clinical trial recruitment, financial and milestone communications, corporate communications, product launches and post-market publicity.

Public

Relations Executive, Feintuch Communications, Lippert/Heilshorn and Manning Salvage & Lee.

Rx COMMUNICATIONS CURRENT CLIENT LIST

Admedus Ltd. (ASX – Australian Market: AHZ)Alexandria Real Estate Equities, Inc. (NYSE: ARE)Bellerophon Therapeutics LLC (Nasdaq: BLPH)Cell Medica Ltd. (Private)Ceramedix, Inc. (Private)CollPlant Holdings Ltd. (TASE: CLPT)Corvidia Therapeutics (Private)CytoPherx, Inc. (Private)Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA)Ion Beam Applications, S.A. or IBA (Euronext Brussels: IBAB)MAXIMUS, Inc. (NYSE: MMS)MDxHealth, S.A. (Euronext: MDXH)

Rx COMMUNICATIONS CURRENT CLIENT LIST

Nanotherapeutics, Inc. (Private) Ophthotech Corporation (Nasdaq: OPHT)OSE Pharma SA (OSE.PA)Orexo AB (Nasdaq OMX: ORX & US OTXOX: ORXOY) Oxford BioMedica Plc (LSE: OXB) PharmAthene, Inc. (NYSE MKT: PIP)Semler Scientific, Inc. (Nasdaq: SMLR)Sequana Medical AG (Private)Therabron Therapeutics, Inc. (Private)Vigilant Biosciences, Inc. (Private)Zealand Pharma A/S (Nasdaq: OMX Copenhagen: ZEAL)

OURx SUCCESSES

Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 95% today.

Launched not-for-profit Immune Tolerance Institute resulting in broad coverage in the U.S. including CBS Radio Network,

San Francisco Business Times

and

Drug Discovery News.

Garnered coverage for Catalyst Pharmaceutical Partners’ compound for cocaine addiction. Placements included cover stories in

Newsweek, Scientific American Mind

and

NeuroInvestment.

OURx SUCCESSES

Designed and implemented assertive investor outreach program for PDI which doubled trading volume and tripled its stock price within nine months.

Arranged feature coverage focused on Hodgkins and non-Hodgkins lymphoma for MethylGene with

Genetic Engineering News, Pink Sheet, BioCentury

and

Pharmawire

Implemented aggressive IR program for PharmAthene, Inc. which enabled the company to obtain coverage from two new sell-side analysts, garner investments from four new institutional funds and increase trading volume by three-fold within nine months.

OURx SUCCESSES

Generated feature articles with Dow Jones Newswire, BioWorld Today, FierceBiotech for the TetraLogic Pharmaceuticals Series C financing.

Devised communications campaign to increase visibility of Amorcyte’s enriched bone marrow stem cell therapy by maximizing clinical data presented at American College of Cardiology (ACC) conference. Leveraged key opinion leaders who presented Amorcyte’s data to gain media coverage, surpassing competitors with later stage clinical data and larger operating budgets. News coverage included: Reuters, CBS Radio Network,

Start-Up Magazine

&

Pharmawire.

OURx SUCCESSES

Generated news coverage with Dow Jones Newswire, Wall Street Journal.com, Drug Discovery & Development for launch of Neovacs autoimmune disease therapeutics.

Developed compelling key messages and arranged media interviews surrounding ZIOPHARM Oncology sarcoma clinical trials resulting in news coverage from Bloomberg Television, Reuters Newswire, BusinessWeek, Associated Press, Wall Street Journal and Forbes.

Within nine months, re-positioned MAXIMUS from a business processing company to a health care services company. Garnered health care sell-side research coverage from Bank of America and Citigroup Global Markets.

OURx SUCCESSES

We are pleased to announce that Rx

Communications has been selected by PR Week

as a finalist forBoutique PR Agency of the Year

Rx Communications was named Best Small PR Agencyby League of American Communications Professionals

Rx Communications Group was honored with

the

Stevie Award for

Best Investor Relations Program

for work on behalf of specialty

pharmaceutical company, NexMed, Inc.

OURx SUCCESSES

Rx Communications was honored with the

SABRE

Awards

Certificate of Excellence for Building a North

American Investor Base for client Syngenta AG.

We are also pleased to share that our work for ImpactRx has won an Honorable MentionAward in LACP’s (League of AmericanCommunications Professionals) Publicity Campaign Competition.

Rx Communications received an honorable Mention

Award from PR News, as part of the PR News Platinum PR

Awards.

The award was issued in the

Financial/Investor Relations category, for the company'swork on behalf of Genaissance Pharmaceuticals, Inc.

WHY Rx COMMUNICATIONS?

Specialist industry knowledge and expertise

Personal attention from Rx partners

Decades of experience in strategic counsel and implementation of financial public relations programs

Unique niche in working with private companies

Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions

“The Street” knows and trusts us

For Additional Information:

Rx Communications Group, LLC

555 Madison Avenue

5

th

Floor

New York, NY 10022

(917) 322-2568

www.RxIR.com